6 days ago
CORT
AnalystsEdward NashEdward Nash's Stock Forecasts
AnalystsEdward Nash
Sectors:
Analyst Ranking
Top 9%
#424 out of 5017 analysts
Average Return
+23.37%
Win Rate
51%39 out of 76
Risk vs Reward
Poor
Good
Edward Nash's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Verona Pharma PLCVRNA | +511.40% | $15.44 | $94.40 | 2024-06-26 - 2025-06-26 | Strong Buy |
Verona Pharma PLCVRNA | +357.91% | $22.88 | $104.77 | 2024-07-21 - 2025-07-09 | Strong Buy |
Cardiol Therapeutics IncCRDL | +267.80% | $0.59 | $2.17 | 2023-05-18 - 2024-05-17 | Strong Buy |
Travere Therapeutics IncTVTX | +195.56% | $6.75 | $19.95 | 2024-05-06 - 2025-05-06 | Strong Buy |
Verona Pharma PLCVRNA | +172.91% | $38.39 | $104.77 | 2024-11-04 - 2025-07-09 | Strong Buy |
Edward Nash Analyst Color
Get additional color on Edward Nash's coverage of popular stocks
a month ago
MDGL
4 months ago
MDGL
5 months ago
TVTX
5 months ago
CORT
7 months ago
VRNA
7 months ago
TVTX
8 months ago
CORT
8 months ago
AKRO
10 months ago
VRNA
a year ago
TVTX
2 years ago
CORT
2 years ago
CRDL
2 years ago
AKRO
2 years ago
AKRO
3 years ago
VTYX
3 years ago
TVTX
3 years ago
VTYX
4 years ago
VRNA
Edward Nash's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | 9 | Strong Buy | $526.00 | +23.59% | Maintains | 4 days ago |
Corcept Therapeutics IncCORT | 9 | Strong Buy | $140.00 | +101.35% | Maintains | 6 days ago |
Celldex Therapeutics IncCLDX | 2 | Strong Buy | $62.00 | +153.06% | Maintains | a month ago |
Sagimet Biosciences IncSGMT | 1 | Strong Buy | $28.00 | +340.25% | Initiates Coverage On | 2 months ago |
Verona Pharma PLCVRNA | 8 | Hold | $107.00 | +0.59% | Downgrades | 2 months ago |
Travere Therapeutics IncTVTX | 10 | Strong Buy | $47.00 | +104.26% | Maintains | 5 months ago |
Rani Therapeutics Holdings IncRANI | 2 | Strong Buy | $9.00 | +1,744.26% | Maintains | 7 months ago |
Pliant Therapeutics IncPLRX | 2 | Hold | $4.00 | +161.44% | Downgrades | 7 months ago |
Akero Therapeutics IncAKRO | 5 | Strong Buy | $73.00 | +70.36% | Maintains | 8 months ago |
Apogee Therapeutics IncAPGE | 1 | Strong Buy | $89.00 | +141.45% | Initiates Coverage On | 10 months ago |
Ventyx Biosciences IncVTYX | 6 | Strong Buy | $14.00 | N/A | Maintains | a year ago |
Cardiol Therapeutics IncCRDL | 3 | Strong Buy | $8.00 | N/A | Maintains | a year ago |
Inventiva SaIVA | 2 | Strong Buy | $20.00 | N/A | Maintains | a year ago |
Morphic Holding IncMORF | 2 | Strong Buy | $66.00 | N/A | Maintains | 2 years ago |
Intercept Pharmaceuticals IncICPT | 7 | Hold | $19.00 | N/A | Downgrades | 2 years ago |
Theratechnologies IncTHTX | 4 | Hold | $8.00 | N/A | Assumes | 2 years ago |
Dice Therapeutics IncDICE | 3 | Hold | $48.00 | N/A | Downgrades | 2 years ago |
Oramed Pharmaceuticals IncORMP | 2 | Hold | $2.00 | N/A | Maintains | 2 years ago |
Amryt Pharma PLCAMYT | 2 | Hold | $17.00 | N/A | Downgrades | 3 years ago |
Galmed Pharmaceuticals LtdGLMD | 2 | Hold | $180.00 | N/A | Downgrades | 3 years ago |
Chemocentryx IncCCXI | 2 | Hold | $52.00 | N/A | Downgrades | 3 years ago |
Rezolute IncRZLT | 1 | Strong Buy | $17.00 | N/A | Assumes | 3 years ago |
Obseva SaOBSVF | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 3 years ago |
Metacrine IncMTCR | 1 | Hold | $1.00 | N/A | Downgrades | 4 years ago |
Adverum Biotechnologies IncADVM | 3 | Hold | $80.00 | N/A | Maintains | 6 years ago |
Ultragenyx Pharmaceutical IncRARE | 2 | Strong Buy | $54.00 | N/A | Maintains | 7 years ago |
Entasis Therapeutics Holdings IncETTX | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 7 years ago |
Uniqure NvQURE | 1 | Strong Buy | $48.00 | N/A | Initiates Coverage On | 7 years ago |
Abeona Therapeutics IncABEO | 1 | Strong Buy | $650.00 | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.